Grape King Bio Ltd (1707) - Total Assets
Based on the latest financial reports, Grape King Bio Ltd (1707) holds total assets worth NT$14.49 Billion TWD (≈ $456.50 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 1707 net assets for net asset value and shareholders' equity analysis.
Grape King Bio Ltd - Total Assets Trend (2002–2024)
This chart illustrates how Grape King Bio Ltd's total assets have evolved over time, based on quarterly financial data.
Grape King Bio Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Grape King Bio Ltd's total assets of NT$14.49 Billion consist of 36.5% current assets and 63.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 28.3% |
| Accounts Receivable | NT$335.53 Million | 2.2% |
| Inventory | NT$813.64 Million | 5.3% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$118.72 Million | 0.8% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Grape King Bio Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Grape King Bio Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Grape King Bio Ltd's current assets represent 36.5% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 28.3% of total assets in 2024, up from 2.4% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 5.3% of total assets.
Grape King Bio Ltd Competitors by Total Assets
Key competitors of Grape King Bio Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Grape King Bio Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.80 | 1.73 | 1.13 |
| Quick Ratio | 1.48 | 1.42 | 0.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$2.07 Billion | NT$1.94 Billion | NT$470.85 Million |
Grape King Bio Ltd - Advanced Valuation Insights
This section examines the relationship between Grape King Bio Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.78 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -1.2% |
| Total Assets | NT$15.32 Billion |
| Market Capitalization | $525.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Grape King Bio Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Grape King Bio Ltd's assets decreased by 1.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Grape King Bio Ltd (2002–2024)
The table below shows the annual total assets of Grape King Bio Ltd from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$15.32 Billion ≈ $482.78 Million |
-1.21% |
| 2023-12-31 | NT$15.51 Billion ≈ $488.71 Million |
+3.05% |
| 2022-12-31 | NT$15.05 Billion ≈ $474.25 Million |
+7.06% |
| 2021-12-31 | NT$14.06 Billion ≈ $442.99 Million |
+7.30% |
| 2020-12-31 | NT$13.10 Billion ≈ $412.85 Million |
+15.36% |
| 2019-12-31 | NT$11.36 Billion ≈ $357.87 Million |
+6.68% |
| 2018-12-31 | NT$10.65 Billion ≈ $335.47 Million |
+7.65% |
| 2017-12-31 | NT$9.89 Billion ≈ $311.64 Million |
+3.58% |
| 2016-12-31 | NT$9.55 Billion ≈ $300.87 Million |
+10.88% |
| 2015-12-31 | NT$8.61 Billion ≈ $271.34 Million |
+60.41% |
| 2014-12-31 | NT$5.37 Billion ≈ $169.15 Million |
+15.99% |
| 2013-12-31 | NT$4.63 Billion ≈ $145.83 Million |
+19.66% |
| 2012-12-31 | NT$3.87 Billion ≈ $121.87 Million |
+11.94% |
| 2011-12-31 | NT$3.46 Billion ≈ $108.87 Million |
+7.95% |
| 2010-12-31 | NT$3.20 Billion ≈ $100.86 Million |
-0.12% |
| 2009-12-31 | NT$3.21 Billion ≈ $100.98 Million |
+23.95% |
| 2008-12-31 | NT$2.59 Billion ≈ $81.47 Million |
+2.36% |
| 2007-12-31 | NT$2.53 Billion ≈ $79.59 Million |
+1.67% |
| 2006-12-31 | NT$2.48 Billion ≈ $78.28 Million |
+4.91% |
| 2005-12-31 | NT$2.37 Billion ≈ $74.61 Million |
-3.53% |
| 2004-12-31 | NT$2.45 Billion ≈ $77.34 Million |
+6.26% |
| 2003-12-31 | NT$2.31 Billion ≈ $72.78 Million |
-6.94% |
| 2002-12-31 | NT$2.48 Billion ≈ $78.21 Million |
-- |
About Grape King Bio Ltd
Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company offers Chinese herbal medicines, probiotics… Read more